Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed ...

(Bloomberg) -- GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK GSK0.69%increase ... settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer. Shares rose 5.6% in morning trade in London, recovering to levels ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance ...

GSK to pay $2.2 billion to settle 93% of Zantac-related lawsuits. GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the ...

Shares of the UK-based pharma giant GlaxoSmithKline PLC (GB:GSK) soared over 6% after the company announced a settlement of up to $2.2 billion for Zantac lawsuits in the U.S. The settlement ...

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer.